A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
AbstractChronic infections have posed a tremendous burden on health care systems worldwide. Approximately 60% of chronic infections are estimated to be related to biofilms, in large part due to the extraordinary antibiotic resistance of biofilm bacteria. Nanoparticle (NP)-based therapies are viable approaches to treat biofilm-associated infections due to NPs' unique chemical and physical properties, granted by their high surface area to volume ratio. The mechanism underlying the anti-biofilmdoi:10.1515/ntrev-2016-0054 fatcat:muu26c44dnflzgw4ljtr5v7dzu